Cancer and New Drugs

Document Sample
Cancer and New Drugs Powered By Docstoc
					                                                  Presented by Daniel Toriola


       Cancer can be treated by surgery, chemotherapy, radiation therapy, immunotherapy, monoclonal antibody
     therapy or other methods. Although radiation damages both cancer cells and normal cells, most normal cells
                                       can recover from the effects of radiation
                                                       Click here to know more



      What Can 5 Bucks Get You? To Start with, 50Gb Web Space, 1 Terrabyte of Data Transfer /month, Unlimited
                     emails IDs and more! Hosted on Blazing Speed Quad Core Servers Only.
                                                       Click here to know more



                                             New Drug Offers Hope to Cancer Patients
                                                         By ARA Content



  New Drug Offers Hope to Cancer Patients
 by: ARA Content

(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of
infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that
human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own
blood supply. But opinion was still divided in the scientific community.

Angiogenesis itself is a natural and necessary physiological function, which refers to the process by
which new blood vessels form and develop. In its pathological form, however, angiogenesis is also
implicated in the progression of more than 20 different diseases, including cancer.

In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and
nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then
invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of
new blood vessels, without which cancerous cells are starved and tumors cannot grow.

In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance.
Indeed, the scientific community now believes that more than 90 percent of all cancer cases are
angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and
more than 100 research organizations and companies are currently developing angiogenesis-blocking
drugs.

Æterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology
companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary
compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase
ll trial in multiple myeloma, a form of blood cancer.

Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among
competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials.
 Further advantages of Neovastat are that it is orally administered, which makes it convenient for
patients who must receive treatment on a long-term basis, and it may be taken in association with

Cancer Carer.com
Information regarding cancer and care for patients.
                                                                                                                Page 1
                                                  Presented by Daniel Toriola


standard therapies such as chemotherapy.

Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that
insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without
suffering from the often debilitating side-effects that some treatments can produce.

Æterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new
therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and
European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of
cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II
trials with 125 patients in the United States, Canada and Europe. This trial should be completed in
early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the
United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung
cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in
the United States and Canada. This trial should be completed in 2005.

Once the clinical trials are complete, health authorities in various countries can then assess these
results and make decisions on approval.




Courtesy of ARA Content, www.ARAcontent.com; e-mail: info@ARAcontent.com

EDITOR'S NOTE: For more information about current trials call (888) 349-3232. For additional
information, contact Paul Burroughs, director of communications, (418) 652-8525, Ext. 406. Neovastat
is being developed by Æterna Laboratories of Quebec, Canada.

To learn more about anti-angiogenesis and Æterna Laboratories, visit the Æterna Web site at
www.aeterna.com. For more information about the NCI's clinical trials, visit
http://cancertrials.nci.nih.gov.




Richardson Cancer Diet By Dr. Janet Hull
A natural effective cancer diet for people with cancer or for the prevention of cancer.
                                                                                                         Page 2
                                               Presented by Daniel Toriola


                      Combination of Therapies May Successfully Treat Pancreatic Cancer
                                                                By Peter Kent



 The University of Pittsburg Cancer Institute (UPCI) recently conducted a study in which researchers
found that the combination of chemotherapy, biotherapy and radiotherapy on pancreatic cancer
patients prior to surgery was beneficial, according to a Science Daily news article.

The study followed approximately 14 patients who had "potentially operable tumors" and all of the
patients were to undergo the combination of treatments before having undergone surgery. Following
the implementation of the "treatment regime" approximately 10 were able to have surgery and the
"incidence of serious adverse events following surgery was not increased in these patients, and
several demonstrated significant shrinkage of their tumors before surgery," according to the news
article.

The study provides significant proof that of by implementing all three therapies, patients that have
developed pancreatic cancer may be able to rid their bodies of the deadly and tumor-induced
condition.

What is Pancreatic Cancer?

According to the National Library of Medicine (NLM), which is part of the National Institutes of Health
(NIH), pancreatic cancer is "the fourth-leading cause of cancer death in the United States." The NLM
reported that the risk factors for this condition include:

* smoking

* diabetes

* chronic pancreatitis

* hereditary/family conditions/disorders

In addition to these risk factors, there is another, less common cause of the development of pancreatic
cancer, which includes the consumption of a prescription drug known as Byetta. The drug Byetta
(exenatide) is used to treat type 2 diabetes among adults and is administered through a twice-a-day
injection.

The drug became available for market use in April 2005 from Amylin Pharmaceuticals and Eli Lilly and
Company. However, following the development of approximately 30 cases of acute pancreatitis and
sudden pancreatic inflammation in October 2007, the U.S. Food and Drug Administration (FDA) began
investigating the drug, but issued no Byetta recall.

Again, in August 2008, several Byetta patients were hospitalized for pancreatic-induced conditions. Of
the six patients admitted to the hospital following their reported conditions, two patients died.
Individuals who consumed Byetta for their type 2 diabetes condition are encouraged to contact a
medical professional immediately as well as a personal injury lawyer or a pharmaceutical attorney to
better understand how to develop a Byetta class action lawsuit that may increase the monetary


Cancer Cure Secrets
Overcome Cancer! - the source for information on cancer cures.High conversion & aff. payout.
                                                                                                          Page 3
                                                   Presented by Daniel Toriola


compensation or reward of a Byetta victim.

It is imperative that a patient suffering from the Byetta side effects as well as diabetes empower
themselves with as much knowledge as possible as it may mean a successful outcome versus a poor
one.



For the latest on the Byetta dangers visit the information portal at http://byetta.legalview.info/ .
Additionally, individuals can also learn about other legal and pharmaceutical controversies such as the
Chantix dangers or the Baxter Herparin recall, all are located at the LegalView library at
http://www.legalview.info/ .




Cancer-Free
Gentle, non-toxic healing of cancer is not only possible - I've done it for over 600 people in the last 3 years.
                                                                                                                   Page 4
                                     Presented by Daniel Toriola




Related eBooks:

Combination of Therapies May Successfully Treat Pancreatic Cancer
Cancer Treatment - Conquer Ovarian Cancer Article
Pancreatic Cancer Patients Find Promising Treatment That Diminishes Tumor Size
An Introduction to Complementary Medicine
Finding Prostate Cancer Treatment Options

Get more Free PDF eBooks at FreePDFeBooks.com

Related Products:

Use and Abuse of Steroids
Take Control of Alcohol
How To FINALLY Stop Smoking...Once and For All!
Tattoo Secrets
Meta Manager


Malamaal.com: A genuine resource center for Quality Ebooks and Softwares

                        This PDF eBook is for free Distribution only, it cannot be SOLD
  Nude Photography For Fun & Profit! Earn $1000+ per week photographing beautiful young women in your area!
                                           Click here to know more




Powered By FreePDFeBooks.com
ReBrand this PDF eBook with your Name / URL / ClickBank Affiliate ID for Free




My Cancer Support Coach.Com
Cancer survival - spiritual tools.
                                                                                                          Page 5